Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.62 |
| ▸ | ESRRG | P62508 | 2/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7248838 | 0.86 | LTA4H (0.51) | ESR1ESRRGESR2CHRM1HTR2A | |
| SCHEMBL4693229 | 0.86 | LTA4H (0.60) | ESR1ESRRGHRH3 | |
| SCHEMBL12156529 | 0.83 | ESR1 (0.53) | ESR1ESRRGESR2CHRM1HTR2A | |
| SCHEMBL7246214 | 0.83 | ESR1 (0.54) | ESR1ESRRGESR2 | |
| Hydrochloric Acid SCHEMBL7244122 | 0.82 | ESR1 (0.55) | ESR1ESRRG | |
| SCHEMBL7251610 | 0.81 | LTA4H (0.50) | ESR1ESRRGCHRM1HTR2AMCHR1 | |
| Hydrochloric Acid SCHEMBL7243161 | 0.80 | LTA4H (0.49) | ESR1ESRRGCHRM1HTR2AMCHR1 | |
| SCHEMBL7253482 | 0.80 | SPHK1 (0.55) | ESR1ESRRGHRH3 | |
| SCHEMBL7137303 | 0.79 | LTA4H (0.64) | ESR1ESRRGHRH3 | |
| Hydrochloric Acid SCHEMBL8814965 | 0.79 | ESR1 (0.49) | ESR1ESRRGESR2MCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008100564-A1 | LTA4H MODULATORS AND USES THEROF | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1660492-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | disclosed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | LTA4H, LTC4S, LTB4R | ESR1 3422/4885ESRRG 2937/4885ESR2 3172/4885 |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | ESR1 4798/4885ESRRG 4214/4885ESR2 4475/4885 |
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | ESR1 2594/4885ESRRG 2018/4885ESR2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.